Harnessing the Power of Botanically-Inspired Therapeutics

We develop innovative pharmaceutical grade DMT and Harmala alkaloid based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses

Our Story

Our founding team are some of the foremost experts on botanically inspired psychedelic compounds including having conducted the world’s largest study into the effects of Ayahuasca and DMT-based medicines.

Based on the compelling data and millenia of traditional use, the potential benefits of psychedelic compounds were evident. From this we were drawn to finding a way to develop clinical treatments for the millions of people that suffer with mental illnesses each day.

To this end, we have formulated a range of psychedelic medicines combining the ethos of traditional wisdom with innovative scientific methods.

The company’s main focus involves the development of standardised and purifed plant-based and synthetic DMT ana harmala medicines.

“We are on a mission to not just treat symptoms of mental illness, but to provide medicines which profoundly transform the quality of life for the hundreds of millions of sufferers around the world.”

Our Mission

Our Path Forward

To date we have:

Identified plant sources of our target compounds that can be grown and harvested at commercial scale

Developed unique extraction and purification techniques with CSIRO and IDT (Australia) to create standardised pharmaceutical grade DMT and harmala medicines
Created a tailored psychological therapeutic treatment model with digital therapeutics support
Phase 1 clinical trial completed
Raised $4.5m in Venture Capital alongside a $2m MRFF grant to complete our Phase 2 clinical trials
Several patents lodged and under development